Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Flu Vaccines
Studies from I. Debruijn and co-researchers in the area of flu vaccines published
March 12th, 2008
"In a randomized, observer-blind, three-arm, parallel group, multi-centre trial including 386 elderly subjects in four countries, the immunogenicity and safety was studied of three different trivalent inactivated surface antigen (subunit) influenza vaccine types: a conventional subunit influenza vaccine (SIV, brand: Influvac (R)) and two newer vaccines: a MF59-adjuvanted subunit influenza vaccine (adSIV, brand: Fluad (R)) and a virosomal subunit influenza vaccine (vSIV, brand: Invivac (R)). All vaccines were trivalent containing 15 mu g hemagglutinin of each virus strain as recommended by the World Health Organization for the 2004-2005 season," scientists writing in the journal...
Source: Vaccine Weekly (2008-03-12)
|
